Comments
Mylan Laboratories Ltd has been selected as one of the lead suppliers of anti-retroviral drugs to the South African Department of Health. The tender period is January 1, 2013 to December 31, 2014.
Hyderabad-based Mylan Labs is the Indian subsidiary of Mylan Inc. The value of the contract is Rand 1.12 billion share (about Rs 700 crore), which represents 19.1 per cent of the Rand 5.9 billion tender value (about Rs 4,000 crore), a press release said.
In an announcement, Mylan Labs said the selection was through its South Africa-based subsidiary Mylan (Propriety) Ltd.
As part of this award, Mylan Labs will supply the South African Government with 31 per cent of the 30 million units of triple therapy fixed dose combination (FDC) called for in the tender.
Mylan supplies ARV drugs to more than 120 countries around the world and approximately one-third of HIV/AIDS patients receiving treatment in developing countries depend on a Mylan ARV product.
The company will be entering the South African market with a comprehensive portfolio of ARV drugs, consisting of first- and second-line adult and pediatric therapies, including several dual and triple FDCs, said Heather Bresch, Chief Executive Officer.
>Somasekhar.m@thehindu@thehindu.co.in
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.